Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)

• Company Description    Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Number of Employees: 1,371

• Price / Volume Information    Yesterday's Closing Price: $23.39 Daily Weekly Monthly 20 Day Moving Average: 2,149,019 shares Shares Outstanding: 96.63 (millions) Market Capitalization: $2,260.17 (millions) Beta: 0.16 52 Week High: $43.22 52 Week Low: $18.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.83% -1.98% 12 Week -35.71% -35.79% Year To Date 1.70% 1.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 Leveroni Court - Novato,CA 94949 USA ph: 415-483-8800 fax: 415-483-8810 ir@ultragenyx.com http://www.ultragenyx.com

• General Corporate Information    Officers Emil D. Kakkis - President and Chief Executive Officer Daniel G. Welch - Chairman Howard Horn - Executive Vice President; Chief Financial Officer; Theodore A. Huizenga - Senior Vice President and Chief Accounting Officer Deborah Dunsire - Director Peer Information Ultragenyx Pharmaceutical Inc. (CORR.) Ultragenyx Pharmaceutical Inc. (RSPI) Ultragenyx Pharmaceutical Inc. (CGXP) Ultragenyx Pharmaceutical Inc. (BGEN) Ultragenyx Pharmaceutical Inc. (GTBP) Ultragenyx Pharmaceutical Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90400D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 96.63 Most Recent Split Date: (:1) Beta: 0.16 Market Capitalization: $2,260.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 43.08% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.36 EPS Growth vs. Year Ago Period: 7.19% vs. Previous Quarter: 28.73% Sales Growth vs. Year Ago Period: 25.55% vs. Previous Quarter: 29.43% ROE 12/31/25 - -1,024.42 09/30/25 - -414.39 06/30/25 - -237.56 ROA 12/31/25 - -43.10 09/30/25 - -43.67 06/30/25 - -37.67 Current Ratio 12/31/25 - 2.48 09/30/25 - 1.89 06/30/25 - 2.45 Quick Ratio 12/31/25 - 2.34 09/30/25 - 1.74 06/30/25 - 2.30 Operating Margin 12/31/25 - -85.54 09/30/25 - -91.95 06/30/25 - -87.34 Net Margin 12/31/25 - -85.54 09/30/25 - -91.95 06/30/25 - -87.34 Pre-Tax Margin 12/31/25 - -84.84 09/30/25 - -91.36 06/30/25 - -86.83 Book Value 12/31/25 - -0.83 09/30/25 - 0.09 06/30/25 - 1.60 Inventory Turnover 12/31/25 - 2.22 09/30/25 - 2.04 06/30/25 - 1.99 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 43.32 06/30/25 - 4.42

Powered by Zacks Investment Research ©